Overview

At a Glance

    • In definitive agreement for Hitachi Chemical Co., Ltd. to purchase Caladrius’ remaining 80.1% ownership interest in its PCT subsidiary
      • Transaction will redefine Caladrius as a cell therapeutics-only development company with multiple proprietary technology platforms and significant capital resources to fund future programs
      • Closing expected to occur in May 2017 subject to approval by Caladrius’ shareholders and customer closing conditions
    • Two technology platforms on which to build
      • T regulatory cells for immune modulation
      • CD34 cells for ischemic repair
    • On-going landmark Phase 2 study of CLBS03 in recent onset type 1 diabetes
      • Strategic relationship with Sanford Research (CLBS retains all product rights)
      • ~$12.2 million CIRM grant awarded
    • Phase 2 protocol in critical limb ischemia for CLBS12 ready to initiate in Japan
      • Positive results could qualify product for early conditional approval in Japan
    • Well-funded with cash on hand >$70 million (May 2017)

Stock Chart

Maximum 30 minute delay for quote.

Sign up to our e-mail list to receive Caladrius announcements.


Investor Relations Contact


Lippert/Heilshorn & Associates
Anne Marie Fields
Phone: +1-212-838-3777
E-mail: afields@lhai.com

Media Contact


Caladrius Biosciences, Inc.
Eric Powers
Director of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com

Additional Information About the Transaction and Where to Find it Caladrius intends to file with the Securities and Exchange Commission (“SEC”) and mail to its stockholders a proxy statement in connection with, among other things, the sale to Hitachi Chemical Co. America, Ltd. (“Purchaser”) of the 80.1% membership interest in PCT that Purchaser does not already own (the “Sale”).  Investors and stockholders of Caladrius are urged to read the proxy statement and the other relevant materials when they become available because they will contain important information about Caladrius and the Sale.  The proxy statement and other relevant materials (when they become available), and any other documents filed by Caladrius with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov.  In addition, investors and stockholders may obtain free copies of the documents filed with the SEC by Caladrius by directing such requests to Caladrius Biosciences, Inc., 420 Lexington Avenue, Suite 350, New York, NY 10170, Attn: Jacquelyn Briggs or jbriggs@caladrius.com, Telephone: (646) 606-2221. Participants in the Solicitation Caladrius and its directors and executive officers may, under SEC rules, be deemed to be participants in the solicitation of proxies from Caladrius’ stockholders in connection with the Sale.   Information regarding Caladrius’ directors and executive officers is contained in Caladrius’ proxy statement on Schedule 14A filed with the SEC on May 10, 2016. Additional information regarding the participants in the solicitation of proxies in respect of the Sale and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement when it becomes available. Safe Harbor for Forward Looking Statements This webpage contains forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995, including forward-looking statements regarding the Sale, the possibility of obtaining stockholder or other approvals or consents for the Sale and Caladrius’ future prospects. These statements are neither promises nor guarantees, but involve risks and uncertainties that could cause actual events or results to differ materially from those set forth in the forward-looking statements, including, without limitation:  risks and uncertainties relating to potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Sale; unexpected costs, charges or expenses relating to or resulting from the Sale; litigation or adverse judgments relating to the Sale; risks relating to the completion of the proposed Sale, including the risk that the required stockholder vote might not be obtained in a timely manner or at all, or other conditions to the completion of the Sale not being satisfied; any difficulties associated with requests or directions from governmental authorities resulting from their review of the Sale; any changes in general economic and/or industry-specific conditions; and other risks detailed in Caladrius’ filings with the SEC, including those disclosed under “Item 1A. Risk Factors” in Caladrius’ Annual Report on Form 10-K filed with the SEC on March 17, 2017 and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC.  You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this webpage’s publication. Caladrius does not intend, and disclaims any obligation, to update or revise any forward-looking information contained in this webpage or with respect to the matters described herein.